Northwest Biotherapeutics, Inc.
NWBO
$0.21
-$0.004-1.87%
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -30.00% | 79.58% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -30.00% | 79.58% | |||
| Cost of Revenue | -1.97% | 4.42% | |||
| Gross Profit | 0.13% | -1.63% | |||
| SG&A Expenses | -27.40% | 19.73% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -15.67% | 12.14% | |||
| Operating Income | 15.25% | -10.92% | |||
| Income Before Tax | -8.42% | 2.42% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -8.42% | 2.42% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -8.42% | 2.42% | |||
| EBIT | 15.25% | -10.92% | |||
| EBITDA | 15.70% | -11.19% | |||
| EPS Basic | -2.65% | 5.03% | |||
| Normalized Basic EPS | 9.30% | -1.18% | |||
| EPS Diluted | 0.00% | 0.00% | |||
| Normalized Diluted EPS | 9.30% | -1.18% | |||
| Average Basic Shares Outstanding | 3.64% | 2.20% | |||
| Average Diluted Shares Outstanding | 3.64% | 2.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
